1 |
Ellenhorn MJ, Barceloux DG. Medical toxicology: diagnosis and treatment of human poisoning. New York: Elsevier; 1988. p. 1185-7.
|
2 |
Stanley EF, Drachman DB. Botulinum toxin blocks quantal but not non-quantal release of ACh at the neuromuscular junction. Brain Res 1983;261:172-5.
DOI
|
3 |
Fujinaga Y. Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin. J Biochem 2006;140:155-60.
DOI
|
4 |
Ravenni R, De Grandis D, Mazza A. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence. Neurol Sci 2013;34:1043-8.
DOI
|
5 |
Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol 2010;55:8-14.
DOI
|
6 |
Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-7.
DOI
|
7 |
Guida S, Farnetani F, Nistico SP, et al. New trends in botulinum toxin use in dermatology. Dermatol Pract Concept 2018;8:277-82.
|
8 |
Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg 2008;32:724-30.
DOI
|
9 |
Honeck P, Weiss C, Sterry W, et al. Reproducibility of a fourpoint clinical severity score for glabellar frown lines. Br J Dermatol 2003;149:306-10.
DOI
|
10 |
Carruthers JD, Lowe NJ, Menter MA, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003;112:1089-98.
|
11 |
Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs 2012;26:e1-9.
DOI
|
12 |
Pingel J, Nielsen MS, Lauridsen T, et al. Injection of high dose botulinum-toxin A leads to impaired skeletal muscle function and damage of the fibrilar and non-fibrilar structures. Sci Rep 2017;7:14746.
DOI
|
13 |
Wang L, Sun Y, Yang W, et al. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon 2014;82:52-60.
DOI
|
14 |
Hasegawa K, Watanabe T, Suzuki T, et al. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J Biol Chem 2007;282:24777-83.
DOI
|
15 |
Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 2015;15:1-9.
DOI
|
16 |
de Almeida AT, De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 2007;9 Suppl 1:17-22.
DOI
|
17 |
Gordon PH, Gooch CL, Greene PE. Extensor digitorum brevis test and resistance to botulinum toxin type A. Muscle Nerve 2002;26:828-31.
DOI
|
18 |
Dressler D. Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 2000;247:809-10.
DOI
|
19 |
Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985;103:347-50.
DOI
|
20 |
Frueh BR, Felt DP, Wojno TH, et al. Treatment of blepharospasm with botulinum toxin: a preliminary report. Arch Ophthalmol 1984;102:1464-8.
DOI
|
21 |
Dat A, Chin M, Skinner S, et al. Botulinum toxin therapy for chronic anal fissures: where are we at currently? ANZ J Surg 2017;87:E70-3.
DOI
|
22 |
Naumann M, Boo LM, Ackerman AH, et al. Immunogenicity of botulinum toxins. J Neural Transm (Vienna) 2013;120:275-90.
DOI
|
23 |
Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin: a dose-response study. Dermatol Surg 1996;22:39-43.
DOI
|
24 |
Tsui JK. Botulinum toxin as a therapeutic agent. Pharmacol Ther 1996;72:13-24.
DOI
|
25 |
Camargo CH, Cattai L, Teive HA. Pain relief in cervical dystonia with botulinum toxin treatment. Toxins (Basel) 2015;7:2321-35.
DOI
|
26 |
Kwak S, Kang WH, Rhee CH, et al. Comparative pharmacodynamics study of 3 different botulinum toxin type A preparations in mice. Dermatol Surg 2020;46:e132-8.
DOI
|
27 |
Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 2017;69:200-35.
DOI
|
28 |
Tang-Liu DD, Aoki KR, Dolly JO, et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125Ibotulinum-free neurotoxin: time course of tissue distribution. Toxicon 2003;42:461-9.
DOI
|
29 |
Seo MS, Kim YI, Kang KK, et al. Comparison study of the response with botulinum toxin muscle injection in the ICR mice from three different sources. Lab Anim Res 2019;35:11.
DOI
|
30 |
Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13:150-4.
DOI
|
31 |
Won CH, Lee HM, Lee WS, et al. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg 2013;39(1 Pt 2):171-8.
DOI
|
32 |
Won CH, Kim HK, Kim BJ, et al. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. Int J Dermatol 2015;54:227-34.
DOI
|
33 |
Goschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies. Therapeutic consequences. Exp Neurol 1997;147:96-102.
DOI
|
34 |
Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981;79:734-70.
|
35 |
Carruthers J, Fournier N, Kerscher M, et al. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine: a global, evidence-based botulinum toxin consensus education initiative. Part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatol Surg 2013;39(3 Pt 2):510-25.
DOI
|
36 |
Lorenc ZP, Kenkel JM, Fagien S, et al. Consensus panel's assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics. Aesthet Surg J 2013;33(1 Suppl):35S-40S.
DOI
|
37 |
Krebs KM, Lebeda FJ. Comparison of the structural features of botulinum neurotoxin and NTNH, a non-toxic accessory protein of the progenitor complex. Botulinum J 2008:1:116-34.
DOI
|
38 |
Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D 2010;10:67-73.
DOI
|
39 |
Dressler D, Bigalke H. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. Mov Disord 2002;17:170-3.
DOI
|
40 |
Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004;19 Suppl 8:S92-100.
DOI
|
41 |
Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019;92:e48-54.
DOI
|
42 |
Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010;25:2211-8.
DOI
|
43 |
Ohishi I, Sugii S, Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun 1977;16:107-9.
DOI
|
44 |
Coleman WP 3rd, Sattler G, Weissenberger P, et al. Safety of incobotulinumtoxinA in the treatment of facial lines: results from a pooled analysis of randomized, prospective, controlled clinical studies. Dermatol Surg 2017;43 Suppl 3:S293-303.
DOI
|
45 |
Dressler D, Zettl U, Benecke R, et al. Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? Mov Disord 2000;15:1279-81.
DOI
|
46 |
Dressler D, Bigalke H, Rothwell JC. The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans. J Neurol 2000;247:630-2.
DOI
|
47 |
Kukreja R, Chang TW, Cai S, et al. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon 2009;53:616-24.
DOI
|
48 |
Park JY, Sunga O, Wanitphakdeedecha R, et al. Neurotoxin impurities: a review of threats to efficacy. Plast Reconstr Surg Glob Open 2020;8:e2627.
DOI
|
49 |
Kromminga A, Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann N Y Acad Sci 2005;1050:257-65.
DOI
|
50 |
Kerscher M, Roll S, Becker A, et al. Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res 2012;304:155-61.
DOI
|
51 |
Chen F, Kuziemko GM, Stevens RC. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun 1998;66:2420-5.
DOI
|
52 |
Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 2010;4:325-32.
DOI
|
53 |
Johnson EA, Bradshaw M. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon 2001;39:1703-22.
DOI
|
54 |
Dodd SL, Rowell BA, Vrabas IS, et al. A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function. Eur J Neurol 1998;5:181-6.
DOI
|
55 |
Frevert J. Xeomin is free from complexing proteins. Toxicon 2009;54:697-701.
DOI
|
56 |
Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel) 2019;11:491.
DOI
|
57 |
Torres S, Hamilton M, Sanches E, et al. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol 2013;7:11-7.
DOI
|
58 |
Rahman E, Alhitmi HK, Mosahebi A. Immunogenicity to botulinum toxin type A: a systematic review with metaanalysis across therapeutic indications. Aesthet Surg J 2022;42:106-20.
DOI
|
59 |
Wang C, Sun T, Li H, et al. Hypersensitivity caused by cosmetic injection: systematic review and case report. Aesthetic Plast Surg 2021;45:263-72.
DOI
|
60 |
Moon IJ, Chang SE, Kim SD. First case of anaphylaxis after botulinum toxin type A injection. Clin Exp Dermatol 2017;42:760-2.
DOI
|
61 |
Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord 2004;19 Suppl 8:S68-84.
DOI
|
62 |
Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003;250:967-9.
DOI
|
63 |
Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50:1624-9.
DOI
|
64 |
Voller B, Moraru E, Auff E, et al. Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A. Mov Disord 2004;19:943-7.
DOI
|
65 |
Hsieh PF, Chiu HC, Chen KC, et al. Botulinum toxin A for the treatment of overactive bladder. Toxins (Basel) 2016;8:59.
DOI
|
66 |
Grein S, Mander GJ, Taylor HV. Xeomin® is stable without refrigeration: Complexing proteins are not required for stability of botulinum neurotoxin type A preparations. Toxicon 2008;51 Suppl 1:13.
DOI
|
67 |
Sellin LC. The pharmacological mechanism of botulism. Trends Pharmacol Sci 1985;6:80-2.
DOI
|
68 |
Munchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ 2000;320:161-5.
DOI
|
69 |
Bhidayasiri R, Truong DD. Evidence for effectiveness of botulinum toxin for hyperhidrosis. J Neural Transm (Vienna) 2008;115:641-5.
DOI
|
70 |
Ferrante FM, Bearn L, Rothrock R, et al. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005;103:377-83.
DOI
|
71 |
Sharma SK, Singh BR. Immunological properties of Hn-33 purified from type A Clostridium botulinum. J Nat Toxins 2000;9:357-62.
|
72 |
Kukreja RV, Singh BR. Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E. Biochemistry 2007;46:14316-24.
DOI
|
73 |
Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006;312:592-6.
DOI
|
74 |
Dressler D, Bigalke H. Immunological aspects of botulinum toxin therapy. Expert Rev Neurother 2017;17:487-94.
DOI
|
75 |
Inoue K, Fujinaga Y, Watanabe T, et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996;64:1589-94.
DOI
|